1. Scrip
  2. >>Focus On Asia

ANALYSIS: Hanmi Deal Strengthens BI’s Hand But Competitors Ahead

 
• By Emily Hayes

Hanmi’s third-generation EGFR inhibitor HM61713, acquired for $50 million up front, strongly complements Boehringer Ingelheim’s existing oncology drug Gilotrif/Giotrif, but the new asset is facing competitors from AstraZeneca and Clovis that are more advanced in development.

Boehringer Ingelheim GMBH’s acquisition of Hanmi Pharmaceutical Co. Ltd.’s third-generation EGFR inhibitor HM61713 helps the private German company build its oncology presence with an essential asset in the targeted lung cancer space, but the Phase II candidate has a lot of catching up to do with some of its rivals.

Boehringer announced plans to buy development and commercialization rights to the drug from South Korean firm Hanmi on July 28, in a transaction worth $50 million up front plus potential milestones of $680 million and royalties

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.